ZBED3-AS1: A Non-Coding RNA Molecule as A Potential Drug Target Or Biomarker

Target Name: ZBED3-AS1

NCBI ID: G728723

ZBED3-AS1

Other Name(s): lnc13728 | ZBED3 antisense RNA 1

ZBED3-AS1: A Non-Coding RNA Molecule as A Potential Drug Target Or Biomarker

ZBED3-AS1 (lnc13728) is a non-coding RNA molecule that has been identified as a potential drug target or biomarker for various diseases, including cancer. Its unique structure and expression pattern have made it an attractive target for researchers to study.

ZBED3-AS1 is a long non-coding RNA molecule that contains 23 exons. It is expressed in various tissues of the body, including the brain, heart, liver, and pancreas. Its expression level varies depending on the tissue and developmental stage of the organism. ZBED3-AS1 has been shown to be involved in various cellular processes, including cell growth, differentiation, and inflammation.

One of the most significant features of ZBED3-AS1 is its expression pattern. It is mainly expressed in the brain, where it is expressed at higher levels than in other tissues. It has been shown to be involved in the development and progression of various neurological disorders, including Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorders.

ZBED3-AS1 has also been shown to be involved in cancer development and progression. It has been found to be overexpressed in various types of cancer, including lung cancer, breast cancer, and colorectal cancer. It has also been shown to be involved in the regulation of cancer cell survival and angiogenesis.

In addition to its potential as a drug target or biomarker, ZBED3-AS1 has also been shown to be a potential therapeutic agent. It has been found to be safe and to have potential therapeutic benefits for various diseases, including cancer. ZBED3-AS1 has been shown to be able to induce apoptosis (programmed cell death) in cancer cells, which can be an effective way to kill cancer cells.

ZBED3-AS1 has also been shown to be involved in the regulation of cellular signaling pathways. It has been found to be involved in the regulation of the PI3K/Akt signaling pathway, a pathway that is involved in various cellular processes, including cell growth, differentiation, and inflammation.

Overall, ZBED3-AS1 is a promising drug target or biomarker for various diseases. Its unique structure and expression pattern make it an attractive target for researchers to study, and its potential as a therapeutic agent makes it a promising addition to the treatment options available for various diseases. Further research is needed to fully understand its role in disease and to develop safe and effective therapies based on it.

Protein Name: ZBED3 Antisense RNA 1

The "ZBED3-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ZBED3-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets